Loay Kassem, Assistant Professor of clinical oncology at Kasr AlAiny School of Medicine, Cairo University, shared a post on LinkedIn:
“The SUPREMO study shows no benefit of adding post mastectomy radiotherapy in patients with N1 disease.
However, this was in patients who had axillary dissection (not the current standard of Sentinel LN).
To me, I would discuss de-escalation of radiotherapy with all patients over 50 years with N1 disease who had ALND.
I would still offer it to most patients with N1 disease who had SLN biopsy.
What would you do regarding PMRT for N1 disease??
Share your insights in the comments.”
Title: Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer
Authors: Ian H. Kunkler, Nicola S. Russell, Niall Anderson, Richard Sainsbury, J. Michael Dixon, David Cameron, Juliette Loncaster, Matthew Hatton, Helen Westenberg, Jackie Clarke, Heather McCarty, Rhun Evans, Konstantinos Geropantas, Virginia Wolstenholme, Abdulla Alhasso, Pamela Woodings, Lisa Barraclough, Neil Bayman, Richard Welch, Fidelis Muturi, Tracy McEleney, Jacqueline Burns, Kathleen Riddle, Eve Macdonald, Joanna Dunlop, Nicole Sergenson, Geertjan van Tienhoven, Karen J. Taylor, John M.S. Bartlett, Tammy Piper, Galina Velikova, Edwin Aird, Boon Chua, Coen Hurkmans, Karen Venables, Linda J. Williams, Jeremy S. Thomas, Andrew M. Hanby, Marjory Maclennan, Susan Cleator, Eldo T. Verghese, Yexiong Li, Shulian Wang, Peter Canney
More posts featuring Loay Kassem on OncoDaily.
